Malik Fady Ibraham 4

What Happened
Malik Fady Ibraham, Executive Vice President, Research & Development at Cytokinetics (CYTK), exercised options to acquire 3,500 shares at an exercise price of $7.80 per share (cost $27,300) on 2026-07-07 and sold 3,500 shares in an open-market transaction the same day at $86.62 per share, for proceeds of $303,170. The filing shows both the option exercise (transaction code M) and the open-market sale (code S).

Key Details

• Transaction date: 2026-07-07 (filed the same day).
• Option exercise: 3,500 shares acquired @ $7.80 each = $27,300 (code M).
• Open-market sale: 3,500 shares sold @ $86.62 each = $303,170 (code S).
• A separate derivative disposition of 3,500 shares is reported at $0.00 (code M) in the filing; no additional explanatory footnote is provided on the Form 4.
• Shares owned after the transaction: not specified in the filing.
• Filing timeliness: transaction and filing date match (no late filing indicated).

Context
This appears to be a same-day exercise-and-sell (cashless) sequence: exercising options and immediately selling the resulting shares is a common way for insiders to cover exercise costs and taxes and to monetize vested awards. Such sales are routine and do not by themselves indicate management’s view of the company’s long-term prospects. The filing is factual and contains no 10b5-1 or other plan disclosures.